Your browser doesn't support javascript.
loading
PD-L1+ macrophages suppress T cell-mediated anticancer immunity.
Liu, Peng; Zhao, Liwei; Kroemer, Guido; Kepp, Oliver.
Afiliación
  • Liu P; Centre de Recherche des Cordeliers, Equipe Labellisée par la Ligue Contre le Cancer, Université de Paris Cité, Sorbonne Université, Institut Universitaire de France, Paris, France.
  • Zhao L; Metabolomics and Cell Biology Platforms, Gustave Roussy Cancer Center, Villejuif, France.
  • Kroemer G; Centre de Recherche des Cordeliers, Equipe Labellisée par la Ligue Contre le Cancer, Université de Paris Cité, Sorbonne Université, Institut Universitaire de France, Paris, France.
  • Kepp O; Metabolomics and Cell Biology Platforms, Gustave Roussy Cancer Center, Villejuif, France.
Oncoimmunology ; 13(1): 2338951, 2024.
Article en En | MEDLINE | ID: mdl-38590800
ABSTRACT
Recently, we showed that an autologous DC-based vaccine induces an increase in immunosuppressive PD-L1+ tumor-associated macrophages (TAM) both in the tumor and the tumor draining lymph nodes, thereby blunting the efficacy of therapeutic immunization. Only the combination of the DC vaccine with anti-PD-L1 immune checkpoint inhibition, but not the use of antibodies targeting PD-1 alone, was able to set off CD8+ cytotoxic T lymphocyte (CTL)-mediated tumor suppression in mice. In sum, we delineated a PD-L1 checkpoint blockade-based strategy to avoid TAM-induced T cell exhaustion during DC vaccine therapy.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Vacunas / Antígeno B7-H1 Límite: Animals Idioma: En Revista: Oncoimmunology Año: 2024 Tipo del documento: Article País de afiliación: Francia Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Vacunas / Antígeno B7-H1 Límite: Animals Idioma: En Revista: Oncoimmunology Año: 2024 Tipo del documento: Article País de afiliación: Francia Pais de publicación: Estados Unidos